News from wuxi apptec A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 28, 2022, 05:09 ET WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR's Bioprocessing Technology Institute (BTI), announced a new...

Apr 25, 2022, 05:52 ET WuXi AppTec Reports Record First-Quarter In 2022

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Apr 07, 2022, 20:00 ET WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics

WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an...

Mar 23, 2022, 07:27 ET WuXi AppTec Reports Strong Revenue Growth in 2021

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Mar 07, 2022, 19:00 ET WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing...

Feb 10, 2022, 21:00 ET WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories

WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, ...

Dec 15, 2021, 19:00 ET Statement by WuXi AppTec Regarding Recent Market Fluctuation

Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the...

Dec 08, 2021, 19:00 ET WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced...

Nov 15, 2021, 07:00 ET WuXi ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support Global Customers

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing...

Oct 29, 2021, 05:41 ET WuXi AppTec Reports Strong Third-Quarter 2021 Results

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Oct 17, 2021, 23:05 ET WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers

WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and...

Sep 05, 2021, 20:00 ET WuXi AppTec Receives AA ESG Rating from MSCI

WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The...

Aug 12, 2021, 05:52 ET WuXi AppTec Reports Strong 2021 Interim Results

WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in...

Aug 03, 2021, 16:07 ET WuXi STA schließt Übernahme der Produktionsstätte von Bristol Myers Squibb in Couvet (Schweiz) ab

WuXi STA - eine Tochtergesellschaft von WuXi AppTec - gab heute bekannt, dass es die Übernahme einer Produktionsstätte für Arzneimittel in Couvet,...

Aug 03, 2021, 15:55 ET WuXi STA finalise l'acquisition de l'usine de fabrication Bristol Myers Squibb à Couvet, en Suisse

WuXi STA, une filiale de WuXi AppTec, a annoncé aujourd'hui qu'elle avait achevé l'acquisition d'une usine de fabrication de produits pharmaceutiques ...

Aug 03, 2021, 07:29 ET WuXi STA adquiere la planta de fabricación de Bristol Myers Squibb en Couvet, Suiza

WuXi STA, una subsidiaria de WuXi AppTec, anunció hoy que ha completado la adquisición de una planta de fabricación de productos farmacéuticos en...

Aug 03, 2021, 07:00 ET WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

WuXi STA – a subsidiary of WuXi AppTec – today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet,...

Apr 29, 2021, 05:59 ET WuXi AppTec Reports Record First-Quarter 2021 Results

WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable...

Mar 30, 2021, 08:59 ET WuXi AppTec Reports Strong 2020 Annual Results

WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in...

Mar 02, 2021, 22:24 ET WuXi AppTec schließt die Übernahme von OXGENE ab und baut damit das Serviceangebot für Zell- und Gentherapie für globale Kunden weiter aus

WuXi AppTec, ein weltweit führender Anbieter von F&E- und produktionsunterstützenden Dienstleistungen in der pharmazeutischen, biotechnologischen und ...

Mar 02, 2021, 20:05 ET WuXi AppTec finalise l'acquisition d'OXGENE pour renforcer encore l'offre de services de thérapie cellulaire et de thérapie génique pour ses clients internationaux

WuXi AppTec, un fournisseur mondial de premier plan de services de R&D et d'aide à la fabrication dans les secteurs pharmaceutique, biotechnologique...

Mar 02, 2021, 09:46 ET WuXi AppTec finaliza la adquisición de OXGENE

WuXi AppTec, un proveedor mundial líder dedicado a los servicios de habilitación de I+D y fabricación en las industrias farmacéutica, biotecnológica...

Mar 02, 2021, 07:30 ET WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device...

Dec 02, 2020, 19:00 ET WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award

WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, ...

Dec 01, 2020, 08:00 ET ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing...